BTG3 and systemic lupus erythematosus: These latter deficiencies (see Table 2) were driven by 14 post-SC cases (all clinically confirmed SLE+) for which manual scrutiny of the MR documents revealed that the genAI first pass generally uncovered ANA status indicators; however, the more stringent second pass scoring was less reliable in confirming that these cases legitimately met EULAR 2019 standards, largely due to cases where relevant records of ANA testing that produced positive determinations occurred prior to the one to two years of compiled medical history made available to this study.